Latest news with #ClinicalTrials
Telegraph
4 days ago
- Health
- Telegraph
Cancer vaccines to be given to patients with deadly head and neck tumours
Cancer vaccines will be given to NHS patients with deadly head and neck tumours. A trial of jabs that could cure people's cancer and prevent it from returning is being expanded to include more than 100 patients with mouth, throat and other head-related cancers, over the next year. The world-first programme has already been trialling personalised cancer vaccines in some 550 patients with either bowel or skin cancers. Tens of thousands of patients will be recruited to trial the various vaccines in development for different forms of the disease over the coming years. The programme, called the NHS Cancer Vaccine Launch Pad, uses a 'match-making' service to partner eligible cancer patients with appropriate trials at nearby hospitals, led by the Southampton Clinical Trials Unit. The cancer vaccines use 'mRNA' technology, first pioneered to create Covid-19 jabs during the pandemic. The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells containing human papillomavirus (HPV) proteins, which are commonly linked to head and neck cancers. Around 11,000 new cases of head and neck cancer are diagnosed in England every year, with a recent University of Sheffield study finding rates had increased by 47 per cent between 2013 and 2020. Aggressive forms of the disease are difficult to treat and have high rates of returning, while fewer than 50 per cent of patients will live for two years after being diagnosed. The vaccine used in the trial is encoded with two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. It trains the body's immune system to attack and kill the cancer cells. Prof Peter Johnson, NHS England's national clinical director for cancer, said it was a 'potentially transformative vaccine, offering renewed hope of holding the disease at bay'. 'The NHS is always looking for evidence-backed innovations in treatment to improve survival and quality of life for people diagnosed with cancer, and this expansion of our Cancer Vaccine Launch Pad will give hundreds of patients the chance to be part of cutting-edge advances in cancer care,' he said. It will be available to selected patients from 15 NHS hospitals over the next 12 months, NHS England said, which is partnering with German life sciences company BioNTech on the programme. The announcement to expand trials into vaccines using mRNA technology comes after Robert F Kennedy Jr, the US health secretary, announced he would cancel $500 million in funding for mRNA vaccines to tackle viruses that cause diseases such as flu and Covid-19. Kennedy, a vaccine sceptic, said he was pulling the funding over claims that 'mRNA technology poses more risks than benefits for these respiratory viruses', in a move that has been heavily criticised. Karin Smyth MP, the health minister, said the new cancer vaccine trial was a 'massive win' for Britain and 'could be game-changing for patients facing some of the most challenging diagnoses'. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation,' she said. Lord Vallance, the science minister and former chief scientific officer for the Government, said: 'Our partnership with BioNTech is delivering for patients right across the country, and I hope to see more ambitious work like this as they continue to invest in research and development and AI as part of their billion-pound backing for the UK over the next 10 years.' Chris Curtis, 67, from Blackpool, was diagnosed with a HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. He said: 'When I was diagnosed with stage four tongue cancer and two secondary cancers, one each side of the neck, my world just fell apart. 'I then had to go through brutal treatment, including six weeks of radiotherapy, chemotherapy every week, two neck dissections and be fed on a tube for almost three years. I lost 12 stone in weight and was severely physically and mentally unwell. 'With this aggressive cancer you live in fear every day – so anything that could help control the disease or give people peace of mind is ground-breaking. 'It'll allow people to get on with their lives and move forward.' Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the launch pad was an 'important route to fast-track promising mRNA vaccine technology into clinical trials'. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone.'
Globe and Mail
5 days ago
- Business
- Globe and Mail
Pulmonary Fibrosis Pipeline Outlook Report 2025: Key 110+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Pulmonary Fibrosis Pipeline Insight 2025' report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Fibrosis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Pulmonary Fibrosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Fibrosis Pipeline Outlook Key Takeaways from the Pulmonary Fibrosis Pipeline Report In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo. In August 2025, Daewoong Pharmaceutical Co. Ltd conducted a phase 2 study to evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis. DelveInsight's Pulmonary Fibrosis Pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment. The leading Pulmonary Fibrosis Companies such as Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Promising Pulmonary Fibrosis Pipeline Therapies such as BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Stay ahead with the most recent pipeline outlook for Pulmonary Fibrosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Fibrosis Treatment Drugs Pulmonary Fibrosis Emerging Drugs Profile BMS-986278: Bristol-Myers Squibb BMS-986278 is a potential first-in-class, oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently being evaluated as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Increased LPA levels and activation of LPA are involved in the pathogenesis of pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of pulmonary fibrosis. AK3280: Ark Biosciences Inc. AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-B) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. LYT-100: PureTech Health LYT-100 (deupirfenidone) is currently in development for idiopathic pulmonary fibrosis (IPF), which is a rare, progressive and fatal disease. LYT-100 is a deuterated form of pirfenidone and is designed to retain the beneficial pharmacology and clinically-validated efficacy of pirfenidone with a highly differentiated pharmacokinetic (PK) profile. In multiple clinical trials, LYT-100 has demonstrated a favorable tolerability profile, which may keep patients on treatment longer to enable more optimal disease management. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. ARO-MMP7: Sarepta Therapeutics ARO-MMP7 is an investigational RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals, aimed at treating idiopathic pulmonary fibrosis (IPF) by targeting and reducing the expression of matrix metalloproteinase 7 (MMP7). This protein is implicated in the pathogenesis of IPF, contributing to inflammation and fibrosis in the lungs. The drug is currently in Phase I/II stage of clinical trial evaluation for the treatment of pulmonary fibrosis. TRK-250: Toray Industries, Inc TRK-250, also known as BNC-1021, is a nucleic acid medicine developed by Toray Industries in collaboration with BONAC Corporation. It is designed to treat Idiopathic Pulmonary Fibrosis (IPF). The drug works by selectively inhibiting the expression of transforming growth factor-beta 1 (TGF-β1), a key protein involved in the fibrotic process at the gene expression level. The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. VUM02 Injection is an innovative therapeutic product developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd. It utilizes human umbilical cord-derived mesenchymal stem cells (hUCT-MSCs). The drug is currently in Phase I stage of clinical trial evaluation for the treatment of pulmonary fibrosis. The Pulmonary Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis Treatment. Pulmonary Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Fibrosis market Explore groundbreaking therapies and clinical trials in the Pulmonary Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Fibrosis Drugs Pulmonary Fibrosis Companies Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Pulmonary Fibrosis Products have been categorized under various Molecule types such as Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Pulmonary Fibrosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Fibrosis Market Drivers and Barriers Scope of the Pulmonary Fibrosis Pipeline Report Coverage- Global Pulmonary Fibrosis Companies- Bristol-Myers Squibb, Ark Biosciences Inc., PureTech Health, Sarepta Therapeutics, Toray Industries, Inc., Wuhan Optics Valley Vcanbiopharma Co., Ltd., Nitto Denko, Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., BreStem Therapeutics, Nuformix, AbbVie, Saniona and others. Pulmonary Fibrosis Pipeline Therapies - BMS-986278, Pirfenidone, Etanercept, BI 1839100, CNTO 888 1 mg/kg, Nintedanib, Pirfenidoneone and others. Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Pulmonary Fibrosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Fibrosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Pulmonary Fibrosis: Overview Therapeutic Assessment Pulmonary Fibrosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) BMS-986278: Bristol-Myers Squibb Drug profiles in the detailed report….. Mid Stage Products (Phase II) AK3280: Ark Biosciences Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) VUM02: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products RSBT 001: RS BioTherapeutics Drug profiles in the detailed report….. Inactive Products Pulmonary Fibrosis Key Companies Pulmonary Fibrosis Key Products Pulmonary Fibrosis- Unmet Needs Pulmonary Fibrosis- Market Drivers and Barriers Pulmonary Fibrosis- Future Perspectives and Conclusion Pulmonary Fibrosis Analyst Views Pulmonary Fibrosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
7 days ago
- Business
- Globe and Mail
RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight
RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' RIPK1 Inhibitor Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market. The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the RIPK1 Inhibitor Pipeline Report: Companies across the globe are diligently working toward developing novel RIPK1 Inhibitor treatment therapies with a considerable amount of success over the years. RIPK1 Inhibitor Key players such as - Sanofi, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharmaceuticals, Sironax, Nuevolution, and others, are developing therapies for the RIPK1 Inhibitor treatment RIPK1 Inhibitor Emerging therapies such as - SAR443122, GFH312, R552, and others are expected to have a significant impact on the RIPK1 Inhibitor market in the coming years. In May 2025, Accropeutics' investigational drug has successfully met the primary objectives in a Phase 2 clinical trial for psoriasis conducted in China, leading the company to commit to accelerating the clinical advancement of its TYK2/JAK1 inhibitor, AC-201. In the trial, 145 Chinese patients with moderate to severe plaque psoriasis were administered one of three doses of AC-201 or a placebo. All dosing groups achieved the primary endpoint, with a significantly higher proportion of patients reaching a 75% improvement in their Psoriasis Area and Severity Score (PASI 75) at Week 12 compared to the placebo group. In October 2024, Sanofi discontinued its Phase 2 clinical trial of oditrasertib, an experimental RIPK1 inhibitor, in patients with relapsing and progressive multiple sclerosis (MS) after the treatment did not achieve its primary objectives. Initiated early last year, the trial failed to demonstrate a significant reduction in neurofilament light chain (NfL) levels — a biomarker associated with neurodegeneration. Additionally, the therapy did not meet any major secondary endpoints, as noted in a recent SEC filing by Denali Therapeutics, Sanofi's development partner. RIPK1 Inhibitor Overview A RIPK1 inhibitor is a type of drug that blocks the activity of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) — an enzyme involved in regulating inflammation, cell death (especially necroptosis), and immune responses. Overactivation of RIPK1 has been linked to several diseases, including autoimmune disorders, neurodegenerative conditions, and inflammatory diseases. By inhibiting RIPK1, these drugs aim to reduce excessive inflammation and tissue damage, offering a promising therapeutic strategy for conditions like multiple sclerosis, Alzheimer's disease, and psoriasis. Emerging RIPK1 Inhibitor Drugs Under Different Phases of Clinical Development Include: RIPK1 Inhibitor Pipeline Therapeutics Assessment RIPK1 Inhibitor Assessment by Product Type RIPK1 Inhibitor By Stage and Product Type RIPK1 Inhibitor Assessment by Route of Administration RIPK1 Inhibitor By Stage and Route of Administration RIPK1 Inhibitor Assessment by Molecule Type RIPK1 Inhibitor by Stage and Molecule Type DelveInsight's RIPK1 Inhibitor Report covers around 12+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Download Sample PDF Report to know more about RIPK1 Inhibitor drugs and therapies RIPK1 Inhibitor Pipeline Analysis: The RIPK1 Inhibitor pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the RIPK1 Inhibitor treatment with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment. RIPK1 Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Scope of RIPK1 Inhibitor Pipeline Drug Insight Table of Contents 1 RIPK1 Inhibitor Report Introduction 2 RIPK1 Inhibitor Executive Summary 3 RIPK1 Inhibitor Overview 4 RIPK1 Inhibitor- Analytical Perspective In-depth Commercial Assessment 5 RIPK1 Inhibitor Pipeline Therapeutics 6 RIPK1 Inhibitor Late Stage Products (Phase II/III) 7 RIPK1 Inhibitor Mid Stage Products (Phase II) 8 RIPK1 Inhibitor Early Stage Products (Phase I) 9 RIPK1 Inhibitor Preclinical Stage Products 10 RIPK1 Inhibitor Therapeutics Assessment 11 RIPK1 Inhibitor Inactive Products 12 Company-University Collaborations (Licensing/Partnering) Analysis 13 RIPK1 Inhibitor Key Companies 14 RIPK1 Inhibitor Key Products 15 RIPK1 Inhibitor Unmet Needs 16 RIPK1 Inhibitor Market Drivers and Barriers 17 RIPK1 Inhibitor Future Perspectives and Conclusion 18 RIPK1 Inhibitor Analyst Views 19 Appendix 20 About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
31-07-2025
- Health
- Yahoo
Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health
Discover key insights with the "Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025." This comprehensive report offers top-line data on Sicca Syndrome (Sjogren) trials worldwide, covering trial numbers, enrollment, regions, phases, and sponsors. Enhance decision-making and gain a competitive edge. Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2025" clinical trials has been added to clinical trial report provides an overview of Sicca Syndrome (Sjogren) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Sicca Syndrome (Sjogren) to Immunology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Sicca Syndrome (Sjogren) to Immunology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Prominent Drugs Latest Clinical Trials News on Sicca Syndrome (Sjogren) Jun 10, 2025: argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease May 28, 2025: Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-Free RNA in Polytrauma Patients Apr 30, 2025: Cullinan Therapeutics to begin US trial of CLN-978 to treat Sjogren's disease Apr 29, 2025: HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society Apr 21, 2025: Immunovant Announces Next Phase of Growth With Roivant Including Changes to Its Leadership Team and Additional Indications SjD and CLE for IMVT-1402 Apr 14, 2025: Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjogren's Syndrome in Taiwan Clinical Trial Profile Snapshots Appendix Top Companies Participating in Sicca Syndrome (Sjogren) Therapeutics Clinical Trials Novartis AG Bristol-Myers Squibb Co ICON Plc AbbVie Inc Parexel International Corp Thermo Fisher Scientific Inc Amgen Inc Laboratory Corp of America Holdings IQVIA Holdings Inc Syneos Health Inc For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-07-2025
- Business
- Yahoo
Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
Discover key insights with the "Renal Failure - Global Clinical Trials Review, 2025." This comprehensive report offers an overview of Renal Failure clinical trials, covering trial numbers, phases, statuses, and sponsor types globally. Stay ahead with data-driven decisions and gain competitive advantage. Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Renal Failure - Global Clinical Trials Review, 2025" clinical trials has been added to clinical trial report provides an overview of Renal Failure Clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive The report provides a snapshot of the global clinical trials landscape Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment The Report provides enrollment trends for the past five years Report provides latest news for the past three months Reasons to Buy Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Renal Failure to Genito Urinary System Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Renal Failure to Genito Urinary System Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Prominent Drugs Clinical Trial Profile Snapshots Appendix Top Companies Participating in Renal Failure Therapeutics Clinical Trials Bayer AG AstraZeneca Plc Amgen Inc Sanofi Novartis AG AbbVie Inc Roche Holding AG Pfizer Inc Takeda Pharmaceutical Co Ltd Astellas Pharma Inc For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
